NLRC4

Across TCGA pan-cancer cohorts, NLRC4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NLRC4 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NLRC4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLRC4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where NLRC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.397	0.851	.001	30	view →
HNSC	DFS	Median	All	0.904	1.000	.002	10	view →
CCRCC	DFS	Median	All	0.918	0.596	.015	8	view →
LUAD	DFS	Median	All	0.625	0.910	.013	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NLRC4–PDAC (DFS)

Open the PDAC breakdown →